Heterozygous carriers of the C allele (CT-genotype) had higher concentrations of serum CCL18 levels, higher CCL18 mRNA expression and decreased survival compared to homozygous carriers of the common T allele [18] in a Dutch IPF-cohort predating the introduction of antifibrotic therapy. This evidence concerns the gene CCL18 and idiopathic pulmonary fibrosis.